Atlas Trials

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia

Clinical trial NCT02720263 · COMPLETED

Trial details

NCT number
NCT02720263
Sponsor
Astellas Pharma Global Development, Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Schizophrenia
Start date
2016-03-28
Primary completion
2017-06-08
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.